1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Immunohistochemical findings in 14 eyes with retinoblastoma
Case No./Sex/Age (mo) AES VEGF Flt-1 CD31
Enhancement Iris Surface Iris Stroma Iris Surface Iris Stroma^a IA^b
1/M/2 Normal Strong Weak Weak Weak 1
2/F/25 Normal Weak Negative Negative Negative 0
3/M/4 Normal Strong Weak Weak Weak 0
4/M/12 Normal Negative Negative Negative Negative 0
5/M/31 Normal Strong Weak Negative Weak 0
6/F/26 Moderate Weak Negative Negative Weak 0
7/F/16 Moderate Strong Weak Strong Weak 3
8/F/2 Moderate Strong Weak Negative Weak 0
9/M/2 Moderate Strong Strong Negative Weak 0
10/M/36 Strong Weak Negative Negative Weak 1
11/F/20 Strong Negative Negative Negative Weak 2
12/M/29 Strong Weak Negative Negative Weak 3
13/M/6 Strong Strong Weak Strong Strong 2
14/M/3 Strong Strong Weak Negative Weak 1
a Significant correlation between AES enhancement and the data in this column (r = .555; P = .04)
b Significant correlation between AES enhancement and the data in this column (r = .665; P = .009). IA according to the Pe'er classification.¹²